---
title: "東陽光藥與深圳晶泰控股簽署人工智能藥物研發框架協議"
description: "陽光湖藥業與深圳晶泰控股簽署人工智能藥物研發框架協議"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/273785942.md"
published_at: "2026-01-27T04:12:44.000Z"
---

# 東陽光藥與深圳晶泰控股簽署人工智能藥物研發框架協議

> 陽光湖藥業與深圳晶泰控股簽署人工智能藥物研發框架協議

### Related Stocks

- [512290.CN - 國泰中證生物醫藥ETF](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [513060.CN - 博時恆生醫療保健(QDII-ETF)](https://longbridge.com/zh-HK/quote/513060.CN.md)
- [159992.CN - 創新藥](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [520690.CN - 博時恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [513120.CN - 廣發中證香港創新藥(QDII-ETF)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [159316.CN - 易方達恆生港股通創新藥ETF](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [02228.HK - 晶泰控股](https://longbridge.com/zh-HK/quote/02228.HK.md)
- [588130.CN - 華夏上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588130.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |
| Beijing Tong Ren Tang Chinese Medicine Co. Ltd. Held Extraordinary General Meeting | Beijing Tong Ren Tang Chinese Medicine Co. Ltd. held an extraordinary general meeting on February 11, 2026, where all pr | [Link](https://longbridge.com/zh-HK/news/275583242.md) |
| Abbisko Cayman Board to Approve Audited Annual Results and Consider Final Dividend | Abbisko Cayman Ltd. will hold a board meeting on March 2, 2026, to approve its audited annual results for the year endin | [Link](https://longbridge.com/zh-HK/news/275573355.md) |
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
